@article{article_391241, title={The Results Of Intravesical Bcg Therapy in The Management of Superficial Bladder Tumors}, journal={Journal of Uludağ University Medical Faculty}, volume={31}, pages={31–34}, year={2005}, author={Çalışkan, Zülküf and Sökmen, Ali and Kordan, Yakup and Vuruşkan, Hakan and Çift, Ali and Yavaşçaoğlu, İsmet and Oktay, Bülent and Ocakoğlu, Gökhan}, keywords={Bladder neoplasms, Intravesical BCG administration, Recurrence, Disease progression}, abstract={In this study, we aimed to evaluate the efficacy of Bacillus Calmette-Guerin (BCG) therapy administered intravesically in patients with superficial bladder tumors carrying moderate to high risk of recurrence. Fifty five patients undergoing transurethral resection of bladder tumors (TUR-BT) for the treatment of superficial transitional cell bladder tumor between 1992 and 2003 were included in the study. Three weeks after the resection, the patients received 81 mg of Pasteur BCG intravesically once a week for 6 weeks. In 27 of the patients, this therapy was continued as once a month for 6 months following the 6 weeks treatment period. TUR-BT was performed in patients who were determined to have recurrence of the tumor and, grade, stage and progression of the tumor and the time period of the recurrences were recorded. Recurrences were observed in 15 (27%) of 55 patients who have been followed up for 36.42±3.16 months in average (12- 126 months). In 2 (13%) of 15 patients having recurrences, there was an increase in the grade as well as stage of the tumor histopathologically. Intravesical BCG immunotherapy applied after TUR-BT is an effective therapeutic option to prevent recurrence and progression of the superficial bladder tumors carrying moderate and high risk of recurrence.}, number={1}, publisher={Bursa Uludağ University}